LBL-061 / Leads Biolabs - LARVOL DELTA

LBL-061: A novel EGFR×PD-L1 targeted drug conjugate for the treatment of multiple solid tumors (AACR 2026) - "Our findings indicate that LBL-061, a novel bispecific EGFR×PD-L1-targeting ADC synergizes antitumor effects by combining direct cytotoxicity and immune activation. It showed a favorable PK profile and a good safety profile in cynomolgus monkeys. Taken together, these preclinical data strongly suggest that LBL-061 is a promising candidate worthy of further clinical investigation."

IO biomarker • Head and Neck Cancer • Lung Cancer • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • EGFR • PD-L1